 | These are a few great ideas for the upcoming week. They are in no particular order but they are the companies that I'll be investing in as funds become available in my accounts. They're each showing a nice estimated one year return on investment, increasing earnings, and pay at least a minimal dividend. I believe that each one of these has a greater potential return than analysts currently expect. As with all investments, I always start with a small position and then add to that position over time with direct purchases, dividend reinvestment, and the sale of options. |
NOTE: Based upon my expectation that the market will move higher next week, a great idea would be to buy shares of the ETF SPXL. This ETF seeks daily investment results, before fees and expenses, of 300% of the performance of the S&P 500® Index. The fund creates long positions by investing at least 80% of its assets in the securities that comprise the S&P 500® Index and/or financial instruments that provide leveraged and unleveraged exposure to the index. These financial instruments include: futures contracts; options on securities, indices and futures contracts; equity caps, floors and collars; swap agreements; forward contracts; short positions; reverse repurchase agreements; exchange-traded funds; and other financial instruments. It is non-diversified.
Apple Inc. designs, manufactures, and markets mobile communication and media devices, personal computers, watches, and portable digital music players worldwide. The company also sells related software, services, accessories, networking solutions, and third-party digital content and applications. It offers iPhone, a line of smartphones that comprise a phone, music player, and Internet device; iPad, a line of multi-purpose tablets; Mac, a line of desktop and portable personal computers; iPod, a line of portable digital music and media players, such as iPod touch, iPod nano, and iPod shuffle; and Apple Watches, personal electronic devices that combine watch technology with an iOS-based user interface. The company also provides iTunes app and the iTunes Store; Mac App Store that allows customers to discover, download, and install Mac applications; iCloud, a cloud service; Apple Pay for making mobile payments; Apple TV, a portfolio of consumer and professional software applications; iOS and OS X operating systems software; iLife, a consumer-oriented digital lifestyle software application suite; iWork, an integrated productivity suite designed to help users create, present, and publish documents, presentations, and spreadsheets; and other application software, including Final Cut Pro, Logic Pro X, and its FileMaker Pro database software. In addition, it offers various Apple-branded and third-party Mac-compatible and iOS-compatible accessories, including headphones, cases, displays, storage devices, and various other connectivity and computing products and supplies. The company sells and delivers digital content and applications through the iTunes Store, App Store, iBooks Store, and Mac App Store; and sells its products through its retail stores, online stores, and direct sales force, as well as through third-party cellular network carriers, wholesalers, retailers, and value-added resellers. The company was founded in 1977 and is headquartered in Cupertino, California.
(Summary) (Company) (Chart)
(Summary) (Company) (Chart)
| 24 January 2016 Price $101.42 1yr Target $142.67 Analysts 42 Dividend $2.08 Payout Ratio 22.60% 1yr Cap Gain 40.67% Yield 2.05% 1yr Tot Return 42.72% | EPS (ttm) $9.20 EPS next yr $10.49 EPS next 5yr 12.59% 1yr Price Support $132.06 P/E 11.02 PEG 0.88 Beta 0.92 Market Cap $562.32 Bil Revenues $233.72 Bil Earnings $53.39 Bil Profit Margin 22.84% | 1yr EarnGR 42.94% 3yr EarnGR 13.33% 5yr EarnGR 33.70% 1yr DivGR 10.63% 3yr DivGR 11.04% 5yr DivGR --- Quick Ratio 1.10 Current Ratio 1.10 Debt/Equity 0.54 ROA 19.70% ROE 42.90% |
Gilead Sciences, Inc. discovers, develops, and commercializes medicines in areas of unmet medical need in North America, South America, Europe, and the Asia-Pacific. The company’s products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver disease. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaborations with Bristol-Myers Squibb Company, Janssen R&D Ireland, and Japan Tobacco Inc. to develop and commercialize various products. The company was founded in 1987 and is headquartered in Foster City, California.
(Summary) (Company) (Chart)
(Summary) (Company) (Chart)
| 10 January 2016 Price $96.45 1yr Target $123.44 Analysts 16 Dividend $1.72 Payout Ratio 15.75% 1yr Cap Gain 27.98% Yield 1.78% 1yr Tot Return 29.76% | EPS (ttm) $10.92 EPS next yr $12.01 EPS next 5yr 14.10% 1yr Price Support $169.34 P/E 8.83 PEG 0.63 Beta 0.92 Market Cap $139.00 Bil Revenues $31.45 Bil Earnings $16.91 Bil Profit Margin 53.76% | 1yr EarnGR 306.07% 3yr EarnGR 59.97% 5yr EarnGR 39.12% 1yr DivGR --- 3yr DivGR --- 5yr DivGR --- Quick Ratio 2.60 Current Ratio 2.80 Debt/Equity 1.28 ROA 41.60% ROE 102.00% |
Aceto Corporation sources, markets, sells, and distributes pharmaceutical intermediates and active ingredients, finished dosage form generics, nutraceutical products, agricultural protection products, and specialty chemicals. The company operates in three segments: Human Health, Pharmaceutical Ingredients, and Performance Chemicals. The Human Health segment supplies raw materials used in the production of nutritional and packaged dietary supplements, including vitamins, amino acids, iron compounds, and bio chemicals used in pharmaceutical and nutritional preparations. It markets and distributes its generic prescription and over the counter pharmaceutical products to wholesalers, chain drug stores, distributors, and mass market merchandisers. The Pharmaceutical Ingredients segment offers active pharmaceutical ingredients and pharmaceutical intermediates to various generic drug companies. The Performance Chemicals segment provides specialty chemicals, such as antioxidants, photo initiators, catalysts, curatives, brighteners, and adhesion promoters, which make plastics, surface coatings, textiles, fuels, and lubricants; diazos and couplers used in microfilms and blueprints, as well as in the photo tooling of printed circuit boards; and organic intermediates and colorants. Its raw materials are also used in electronic parts and binders. This segment also offers agricultural protection products comprising herbicides, fungicides, and insecticides, which control weed growth and the spread of insects and microorganisms; and sprout inhibitors for potatoes. The company serves various companies in the industrial chemical, agricultural, and human health and pharmaceutical industries primarily in the United States, Europe, and Asia. Aceto Corporation was founded in 1947 and is headquartered in Port Washington, New York.
(Summary) (Company) (Chart)
(Summary) (Company) (Chart)
| 24 January 2016 Price $23.59 1yr Target $37.33 Analysts 3 Dividend $0.24 Payout Ratio 18.60% 1yr Cap Gain 58.24% Yield 1.01% 1yr Tot Return 59.25% | EPS (ttm) $1.29 EPS next yr $1.78 EPS next 5yr 20.00% 1yr Price Support $35.60 P/E 18.29 PEG 0.91 Beta 1.35 Market Cap $695.91 Mil Revenues $549.60 Mil Earnings $38.00 Mil Profit Margin 6.79% | 1yr EarnGR 11.76% 3yr EarnGR 21.61% 5yr EarnGR 34.39% 1yr DivGR 0.00% 3yr DivGR 6.20% 5yr DivGR 3.71% Quick Ratio 2.10 Current Ratio 2.90 Debt/Equity 0.42 ROA 7.80% ROE 15.20% |
Sunoco LP engages in the wholesale distribution and retail sale of motor fuels primarily in Texas, New Mexico, Oklahoma, Louisiana, Kansas, Maryland, Virginia, Tennessee, Georgia, and Hawaii. It operates through two segments, Wholesale and Retail. It serves convenience stores and consignment locations, contracted independent convenience store operators, and other commercial customers. The company also distributes other petroleum products, such as propane and lubricating oils; and leases or subleases real estate properties used in the retail distribution of motor fuels. As of December 31, 2014, it operated 155 convenience stores and fuel outlets offering merchandise, food service, motor fuel, and other services in 5 states. Sunoco GP LLC serves as the general partner of the company. The company was formerly known as Susser Petroleum Partners LP and changed its name to Sunoco LP in October 2014. Sunoco LP is based in Houston, Texas.
(Summary) (Company) (Chart)
(Summary) (Company) (Chart)
| 10 January 2016 Price $36.69 1yr Target $48.57 Analysts 14 Dividend $2.77 Payout Ratio 123.11% 1yr Cap Gain 32.37% Yield 7.54% 1yr Tot Return 39.91% | EPS (ttm) $2.25 EPS next yr $2.89 EPS next 5yr 33.50% 1yr Price Support $96.81 P/E 16.31 PEG 0.49 Beta --- Market Cap $2.73 Bil Revenues $14.75 Bil Earnings $93.30 Mil Profit Margin 0.63% | 1yr EarnGR 10.65% 3yr EarnGR --- 5yr EarnGR --- 1yr DivGR --- 3yr DivGR --- 5yr DivGR --- Quick Ratio 0.90 Current Ratio 1.40 Debt/Equity 1.01 ROA 2.40% ROE 5.10% |
Southwest Airlines Co. operates passenger airlines that provide scheduled air transportation services in the United States and near-international markets. As of December 31, 2014, it operated 665 Boeing 737 aircraft; and had 12 Boeing 717 aircraft. The company served 93 destinations in 40 states, the District of Columbia, and the Commonwealth of Puerto Rico, as well as 5 near-international countries, including Mexico, Jamaica, The Bahamas, Aruba, and the Dominican Republic. It also sells frequent flyer points and related services to business partners participating in the Rapid Rewards frequent flyer program, including car rental agencies, hotels, restaurants, and retail locations. The company was founded in 1967 and is headquartered in Dallas, Texas.
(Summary) (Company) (Chart)
(Summary) (Company) (Chart)
| 24 January 2016 Price $39.00 1yr Target $54.15 Analysts 13 Dividend $0.30 Payout Ratio 10.98% 1yr Cap Gain 38.84% Yield 0.76% 1yr Tot Return 39.60% | EPS (ttm) $2.73 EPS next yr $4.16 EPS next 5yr 29.18% 1yr Price Support $121.38 P/E 15.7714.29 PEG 0.49 Beta 0.95 Market Cap $25.36 Bil Revenues $19.47 Bil Earnings $1.84 Bil Profit Margin 9.45% | 1yr EarnGR 56.19% 3yr EarnGR 91.21% 5yr EarnGR 66.22% 1yr DivGR 144.44% 3yr DivGR 128.43% 5yr DivGR 64.97% Quick Ratio 0.60 Current Ratio 0.60 Debt/Equity 0.41 ROA 8.80% ROE 26.40% |
RSS Feed
